Paper35637337
An early warning system for emerging SARS-CoV-2 variants.
Subissi L and 60 others. Nat Med, 2022. Cited by 61 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. An early warning system for emerging SARS-CoV-2 variants. Papers, record 35637337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35637337
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| SARS-CoV-2 | Major topic |
| Humans |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 001 | World Health Organization | International | PubMed | PubMed | |
| 206298/Z/17/Z | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| MR/R015600/1 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| ZIA AI001324 | Intramural NIH HHS | United States | ZIAAI001324 | PubMed and NIH | NIH RePORTER |
| ZIAAI001289 | NIH | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,735,219 | Rapid assessment of SARS-CoV-2-evolved variants using virus-like particles. | Science | 2021 | https://conductscience.org/library/papers/34735219 | PubMed |
| 2 | 33,723,411 | Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. | Nature | 2021 | https://conductscience.org/library/papers/33723411 | PubMed |
| 3 | 34,461,056 | Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. | Lancet Infect Dis | 2022 | https://conductscience.org/library/papers/34461056 | PubMed |
| 4 | 34,678,071 | Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. | Sci Adv | 2021 | https://conductscience.org/library/papers/34678071 | PubMed |
| 5 | 35,025,969 | Advances and gaps in SARS-CoV-2 infection models. | PLoS Pathog | 2022 | https://conductscience.org/library/papers/35025969 | PubMed |
| 6 | 34,504,335 | The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. | Nat Med | 2021 | https://conductscience.org/library/papers/34504335 | PubMed |
| 7 | 35,042,229 | Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. | Nature | 2022 | https://conductscience.org/library/papers/35042229 | PubMed |
| 8 | 35,042,228 | Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. | Nat Med | 2022 | https://conductscience.org/library/papers/35042228 | PubMed |
| 9 | 35,102,311 | T cell responses to SARS-CoV-2 spike cross-recognize Omicron. | Nature | 2022 | https://conductscience.org/library/papers/35102311 | PubMed |
| 10 | 35,474,744 | Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. | Cell Rep Med | 2022 | https://conductscience.org/library/papers/35474744 | PubMed |
| 11 | 35,014,856 | Predicting the mutational drivers of future SARS-CoV-2 variants of concern. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/35014856 | PubMed |
| 12 | 31,604,969 | Evolutionary, genetic, structural characterization and its functional implications for the influenza A (H1N1) infection outbreak in India from 2009 to 2017. | Sci Rep | 2019 | https://conductscience.org/library/papers/31604969 | PubMed |
| 13 | 34,347,959 | SARS-CoV-2 Variants in Patients with Immunosuppression. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34347959 | PubMed |
| 14 | 33,172,935 | Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. | Science | 2021 | https://conductscience.org/library/papers/33172935 | PubMed |
| 15 | 33,804,556 | SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations. | Viruses | 2021 | https://conductscience.org/library/papers/33804556 | PubMed |
| 16 | 33,761,326 | N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. | Cell | 2021 | https://conductscience.org/library/papers/33761326 | PubMed |
| 17 | 33,684,923 | Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. | Nature | 2021 | https://conductscience.org/library/papers/33684923 | PubMed |
| 18 | 34,931,886 | Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/34931886 | PubMed |
| 19 | 34,166,617 | Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. | Cell Rep | 2021 | https://conductscience.org/library/papers/34166617 | PubMed |
| 20 | 34,818,667 | The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. | Nature | 2022 | https://conductscience.org/library/papers/34818667 | PubMed |
Cited by48
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,598,025 | Nipah virus and the lessons of COVID-19: are we prepared for the next pandemic threat? | Infect Med (Beijing) | 2026 | https://conductscience.org/library/papers/42598025 | PubMed |
| 42,390,251 | Tracking the shifting landscape of SARS-CoV-2 variants in Lebanon among healthcare workers and hospitalized patients. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42390251 | PubMed |
| 42,137,592 | A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42137592 | PubMed |
| 42,009,860 | Risk of stroke following SARS-CoV-2 infection in a nationwide self-controlled case series study in qatar. | Sci Rep | 2026 | https://conductscience.org/library/papers/42009860 | PubMed |
| 41,832,161 | Optimizing global genomic surveillance for early detection of emerging SARS-CoV-2 variants. | Nat Commun | 2026 | https://conductscience.org/library/papers/41832161 | PubMed |
| 41,258,470 | A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023. | Commun Med (Lond) | 2025 | https://conductscience.org/library/papers/41258470 | PubMed |
| 41,062,635 | Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar. | Sci Rep | 2025 | https://conductscience.org/library/papers/41062635 | PubMed |
| 40,177,126 | VirusWarn: A mutation-based early warning system to prioritize concerning SARS-CoV-2 and influenza virus variants from sequencing data. | Comput Struct Biotechnol J | 2025 | https://conductscience.org/library/papers/40177126 | PubMed |
| 40,139,840 | Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities. | BMJ Open Respir Res | 2025 | https://conductscience.org/library/papers/40139840 | PubMed |
| 40,093,761 | Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/40093761 | PubMed |
| 39,910,292 | Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron. | Nature | 2025 | https://conductscience.org/library/papers/39910292 | PubMed |
| 39,770,311 | Genomic Diversity and Evolution of Identified SARS-CoV-2 Variants in Iraq. | Pathogens | 2024 | https://conductscience.org/library/papers/39770311 | PubMed |
| 39,446,192 | Forecasting dominance of SARS-CoV-2 lineages by anomaly detection using deep AutoEncoders. | Brief Bioinform | 2024 | https://conductscience.org/library/papers/39446192 | PubMed |
| 39,236,073 | Surveillance strategies for the detection of new pathogen variants across epidemiological contexts. | PLoS Comput Biol | 2024 | https://conductscience.org/library/papers/39236073 | PubMed |
| 39,162,483 | Report of SARS-CoV-2 JN.1 variant in Morocco. | Microbiol Resour Announc | 2024 | https://conductscience.org/library/papers/39162483 | PubMed |
| 38,720,002 | An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. | Nat Med | 2024 | https://conductscience.org/library/papers/38720002 | PubMed |
| 38,640,902 | SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs. | Cell Chem Biol | 2024 | https://conductscience.org/library/papers/38640902 | PubMed |
| 38,632,281 | Data-driven recombination detection in viral genomes. | Nat Commun | 2024 | https://conductscience.org/library/papers/38632281 | PubMed |
| 38,529,118 | Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/38529118 | PubMed |
| 38,515,050 | Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021. | BMC Infect Dis | 2024 | https://conductscience.org/library/papers/38515050 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35637337
GET https://conductscience.org/api/papers/v1/35637337/authors?page=2